FRNM Freenome, Inc.
$12.72▼ -0.39%
Healthcare
Other
Volume 370.9K
Avg Volume (10D) 789.0K
Key Metrics & Fundamentals
Market Cap
$1.37B
P/E Ratio
–
Div Yield
0.00%
52W Range
9.95 - 17.50
% vs 50 MA
-13.88%
% vs 200 MA
1.55%
RSI-14
40.0
MACD Histogram
-0.1600
Beta (1Y vs SPY)
0.59
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
Freenome Soars 11% on Launch of Lung Cancer Blood Test That Makes Screening “Vastly Easier”
TIKR · Oct 23, 2026 2:23 PM ET
Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option
GlobeNewswire · Oct 20, 2026 8:30 AM ET
Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026
GlobeNewswire · Oct 15, 2026 4:29 PM ET
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
GlobeNewswire · Oct 11, 2026 1:00 PM ET
FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test
GlobeNewswire · Aug 12, 2026 9:00 AM ET
Freenome (FRNM) Climbed, But What Is Driving Attention Now?
Simply Wall St. · Aug 10, 2026 11:19 PM ET
Guardant Health, Thursday's Stock Of The Day, Spikes After Hiking 2026 Outlook
Investor's Business Daily · Jul 31, 2026 4:22 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.